← Eichor
Study identifier: NCT06588595 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Switching Antiplatelet-9 (SWAP-9) Study

Condition: Coronary Arterial Disease (CAD)  ·  Sponsor: University of Florida

PhasePhase 4
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).

This description comes directly from the study's public registry record.

Talk to the study team

Luis Ortega, MD, PhD  ·  904-244 2060  ·  Luis.Ortega@jax.ufl.edu

Andrea Burton, MPH, CCRP  ·  904-244-5617  ·  Andrea.Burton@jax.ufl.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of FloridaJacksonville, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06588595